In this video interview from the 2026 DIA Global Annual Meeting, Joan Chambers, independent senior consultant at Tufts CSDD, explains how the flexibility and accessibility of decentralized trial modalities are expanding patient reach—and why fit-for-purpose deployment is key to making them work.
In a recent video interview with Applied Clinical Trials at the 2026 DIA Global Annual Meeting, Joan Chambers, independent senior consultant at Tufts CSDD, shared her perspectives on decentralized clinical trials following a session she moderated on the topic. She opened by framing DCT as an umbrella concept encompassing a range of modalities—telehealth, mobile apps, in-home nursing visits, mobile vans—each of which can be deployed selectively depending on the needs of a given study. The core value proposition, she argued, is flexibility: by meeting patients where they are, DCT models expand access to populations that have historically been excluded from trials due to geographic or logistical barriers, and that accessibility directly supports both recruitment and retention.
On the operational side, Chambers was candid about the challenges sites face in implementing these models. Sites already manage multiple studies across multiple sponsors, each with its own technology stack. Adding a DCT component introduces yet another layer of complexity—new tools to learn, new workflows for data collection and patient follow-up, and the need to dedicate staff time to managing a fundamentally different type of patient interaction alongside traditional site operations. She identified this technology burden as one of the most common and persistent friction points in DCT implementation at the site level.
Chambers closed with a grounded set of takeaways from the session, cautioning against the assumption that DCT represents a universal solution. The field, she noted, is still defining the term itself, and the evidence base for which specific modalities produce the best outcomes in which contexts is still being built. Her expectation is that as data accumulates over the next several years, it will become clearer which DCT activities are most effective and in which settings—ultimately guiding the industry toward more evidence-based, fit-for-purpose trial designs that bring research to patients who would not otherwise have the opportunity to participate.
